Generic Tablets Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Tablet manufacturing mandates CDSCO manufacturing licence, Schedule M (revised) compliance for Good Manufacturing Practices, and state FDA drug licence. Environmental clearance under EIA Notification 2006 applies for projects above 5-acre site area or effluent generation exceeding threshold limits.

• CDSCO Form 27 / 27A: Manufacturing licence application for allopathic formulations under Drugs and Cosmetics Rules 1945, Rule 74. Inspection by Central Drugs Inspectors post documentation scrutiny. Timeline: 6-9 months for new facility.
• State FDA Drug Licence: Form 25 (for sale) and Form 26 (for manufacturing) under Drugs and Cosmetics Act 1940, Rules 1945. State Licensing Authority (SLA) jurisdiction. Requires qualified competent persons under Rule 85.
• Schedule M / Schedule M-III (Revised): GMP compliance covering premises, equipment, personnel, quality control, documentation, and self-inspection. Mandatory WHO-GMP certification for export-oriented facilities targeting regulated markets.
• Pollution Control Board Consent: Consent to Establish (CTE) under Water (Prevention and Control of Pollution) Act 1974 and Air (Prevention and Control of Pollution) Act 1981. Effluent treatment plant (ETP) specification for pharmaceutical waste. Hazardous Waste Authorisation under HW(MH) Rules 2016.
• BIS Certification (IS 14685:2000): Standards for uncoated and film-coated tablets where applicable for institutional procurement. Voluntary for domestic retail, mandatory for government supply contracts.
• GST Registration and Pharmaceutical Excise: GST registration under GSTN Act 2017 at 12% for essential medicines, 18% for other formulations. EPF and ESI compliance for establishments employing 20+ and 10+ workers respectively.
• Fire NOC and Building Plan Approval: Building plan endorsement from local authority (municipal corporation or gram panchayat) for industrial use. Fire safety clearance from district fire officer under state fire service rules.
• US FDA Facility Registration: If targeting US market, facility registration under FDA 21 CFR Part 207. DMF (Drug Master File) filing for APIs and excipients sourced from approved suppliers. ANDA filing pathway requires USFDA inspection readiness.

KAMRIT Financial Services LLP manages the complete regulatory filing architecture from CDSCO applications through state FDA licensing, Schedule M documentation, pollution consents, and US FDA facility registration where applicable. Our team coordinates with approved consultants and statutory bodies to compress approval timelines to 10-14 months for greenfield tablet facilities.

Tablet formulations subdivide into dispersible, chewable, swallowable, and orally disintegrating variants, each commanding differentiated pricing and margin structures. The chronic disease segment (cardiovascular, diabetes, neurological) grows at 15-18% annually, outpacing the 8-10% growth in acute therapies. Government procurement through Jan Aushadhi stores creates volume upside for cost-competitive manufacturers, while the private retail channel rewards brands with superior brand recall.

Export-oriented units targeting US FDA approvals command 25-40% revenue premiums over domestic-only facilities, reflecting validation costs and compliance infrastructure. The contract manufacturing segment expands at 12% CAGR as multinationals outsource non-core tablet lines. Critical material inputs include lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and coating agents, with import dependency on certain grade-specific excipients creating supply chain exposure.

Formulation development timelines for a new ANDA filing average 18-24 months, while generic domestic launches require 6-9 months from development to market. State-wise clustering in Gujarat, Maharashtra, and Himachal Pradesh benefits from established industrial infrastructure, skilled labour pools, and proximity to active pharmaceutical ingredient (API) manufacturers in Hyderabad and Visakhapatnam.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth

Tablet manufacturing technology spans batch and continuous processing routes. High-shear wet granulation remains the dominant method for Indian facilities, employing high-shear mixers (50-600 litre capacity), fluid bed dryers, and oscillator/rotary granulators. Modern facilities deploy continuous manufacturing lines combining loss-in-weight feeders, twin-screw granulators, and integrated tablet presses, reducing batch cycle times from 4-6 hours to 90-120 minutes.

Compression equipment selection determines throughput: rotary presses with 27-61 stations produce 50,000-300,000 tablets per hour depending on tablet weight and press speed. Major Indian suppliers include ACG (pam-Glatt fluid bed systems, PAM-STAR tablet presses), Cadmach (Rimei rotary presses), and ACG's subsidiary offerings. European equipment from GEA (ConsiGma continuous line), IMA (Acti-Mats), and Bosch (H 120) commands 40-60% cost premiums over Indian alternatives.

Chinese manufacturers like ChinaKexing offer 30-40% lower capital cost with longer validation cycles and service response gaps. Japanese equipment from Hata Iron Works and Kikusui provides intermediate positioning for precision coating applications. Coating technology options include conventional pan coaters (30-50 kg batch capacity) for enteric and film coating, and advanced Wurster fluidised bed coaters achieving 15-25 micron coating uniformity.

Blister packaging lines operate at 30,000-180,000 blisters per hour with PVC/PVDC/Aluminium material combinations. CapEx benchmarks range from ₹14.4 crore for a basic 2-press facility producing 500 million tablets annually to ₹221 crore for a fully automated multi-line plant with continuous granulation, advanced coating, and serialization infrastructure meeting DSCSA/TRACENS compliance. Energy consumption benchmarks at 180-250 kWh per million tablets produced, with natural gas or steam as primary thermal energy sources for drying and coating operations.

The project CapEx band of ₹14.4 crore to ₹221 crore warrants segmented financing strategies. For the ₹14.4-40 crore lower tier, debt financing at 70:30 debt-equity from SIDBI (interest rate: MCLR+50-100 bps for pharma MSMEs), State Bank of India MSME loans, or HDFC Bank healthcare financing suits the profile. PMEGP subsidies up to ₹10 lakh for micro units and CGTMSE guarantee coverage for collateral-free loans up to ₹2 crore reduce effective cost of capital. For mid-tier projects ₹40-120 crore, consortium lending with State Bank of India as lead banker alongside Axis Bank and ICICI Bank healthcare desks provides diversified risk. PLI Scheme for Bulk Drug and Medical Devices offers 5-20% incentive on incremental sales for domestically manufactured formulations, directly improving project IRR by 2-4 percentage points. Upper-tier projects ₹120-221 crore targeting US FDA approvals merit EXIM Bank financing for imported equipment (up to 85% of CIF value) combined with equity from promoter group and strategic investors. Working capital cycle for tablet manufacturing spans 45-65 days, driven by 30-45 day receivable days from institutional buyers (government, hospital chains) and 60-75 days from retail distributors. Inventory norms: 30-45 day raw material stock for critical APIs, 15-20 day finished goods buffer for fast-moving SKUs. Debt service coverage ratio (DSCR) benchmark of 1.35x-1.5x for bank appraisal, with sensitivity analysis on volume realization at 80%, 90%, and 110% of rated capacity during ramp-up phase of 18-24 months.

Three primary risks shape this project's bankable DPR framework. First, regulatory risk manifests through CDSCO inspection delays, Schedule M non-compliance observations, or US FDA warning letters halting export revenues. Mitigation requires engaging third-party consultants for pre-approval inspections, implementing pharmaceutical quality management systems (QMS) with electronic batch records, and maintaining reserved capital (8-12% of CapEx) for remediation and revalidation costs.

Second, raw material price volatility affects API and excipient costs, which constitute 55-70% of COGS for generic tablets. Single-source dependency for critical molecules creates supply disruption exposure. The DPR structures vendor qualification protocols, dual-sourcing agreements for molecules above ₹5 crore annual procurement value, and inventory buffer norms.

Third, competitive pricing pressure from Chinese generic manufacturers and domestic consolidation among listed players compresses realisations, particularly in high-volume chronic disease segments where margin erosion of 8-12% occurs during competitive tender cycles. Sensitivity analysis models revenue scenarios at 85%, 100%, and 115% of base case pricing, demonstrating DSCR remains above 1.25x under 85% volume and 10% price reduction scenario. Mitigation includes product portfolio diversification across 25-40 SKUs, backward integration into critical excipient manufacturing for cost leadership, and contract manufacturing revenue averaging 30% of capacity to stabilise cash flows.